Analysts MLV & Co upgraded Acura Pharmaceuticals, Inc. ACUR from Hold to Buy.
The price target for Acura Pharmaceuticals is set to $1.
Acura Pharmaceuticals shares have dropped 61.62% over the past 52 weeks, while the S&P 500 index has surged 13.51% in the same period.
Acura Pharmaceuticals' shares rose 6.76% to $0.79 in after-hours trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
